Fight Aging! Newsletter, June 12th 2023

In this study, we investigated the effect of NXP032 on neurovascular stabilization through the changes of PECAM-1, PDGFR-β, ZO-1, laminin, and glial cells involved in maintaining the integrity of the blood-brain barrier (BBB) in aged mice. NXP032 was orally administered daily for 8 weeks. Compared to young mice and NXP032-treated mice, 20-month-old mice displayed cognitive impairments in Y-maze and passive avoidance tests. NXP032 treatment contributed to reducing the BBB damage by attenuating the fragmentation of microvessels and reducing PDGFR-β, ZO-1, and laminin expression, thereby mitigating astrocytes and microglia activation during normal aging. Based on the results, we suggest that NXP032 reduces vascular aging and may be a novel intervention for aging-induced cognitive impairment.

SENS Research Foundation's Senotherapeutic Screening Project is Now Crowdfunding at Experiment
https://www.fightaging.org/archives/2023/06/sens-research-foundations-senotherapeutic-screening-project-is-now-crowdfunding-at-experiment/

Experiment is a crowdfunding platform for small scientific projects. It has been running for quite a few years now, one of the few survivors from the first wave of attempts to make crowdfunding platforms to fund scientific research. It is a challenging goal, the motivations and incentives are completely different from those operating in commercial product crowdfunding. SENS Research Foundation is now using Experiment to raise a modest amo...

Source: Fight Aging! - June 11, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs